Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2020-324743DOI Listing

Publication Analysis

Top Keywords

gastric synucleinopathy
4
synucleinopathy prodromal
4
prodromal pathological
4
pathological biomarker
4
biomarker idiopathic
4
idiopathic rem
4
rem sleep
4
sleep behaviour
4
behaviour disorder
4
gastric
1

Similar Publications

A novel levodopa-carbidopa three-layer gastroretentive tablet for improving levodopa pharmacokinetics.

Eur J Pharm Biopharm

February 2025

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, Hunan 410006, China. Electronic address:

The narrow absorption window of levodopa and the significant impact of peripheral decarboxylase are the most limiting factors in maintaining prolonged and smooth plasma concentration in patients with Parkinson's disease (PD). Therefore, this study aims to design a novel gastroretentive carbidopa-levodopa three-layer tablet, which consists of an expansion layer, an immediate-release layer, and a sustained-release layer. The expansion layer rapidly expanded with sufficient structural strength and stayed in the beagle's stomach for more than 10 h, delineating excellent gastric retention effects.

View Article and Find Full Text PDF

Non-, a Treatable Provocateur of Parkinson's Disease: Hypothesis, Evidence and Species Specificity.

Int J Mol Sci

December 2024

Host Microbiome Interaction, Clinical Pharmacology and Therapeutics, Institute of Pharmaceutical Science, King's College London, London SE1 9NH, UK.

Epidemiological and eradication trial evidence indicates that , a major causative factor in peptic ulcer and gastric cancer, is a driver of the hypokinesia of Parkinson's disease (PD). Psychological (cognitive impairment, depression and anxiety) and gastrointestinal (peptic ulceration and constipation) PD features can precede the symptomatic onset of motor features by decades. We hypothesise that the non- (NHPH), which have farm, companion and wild animals as their main hosts, can have a role in PD aetiopathogenesis.

View Article and Find Full Text PDF

Objectives: To analyze the regularity of acupoint selection and compatibility of acupuncture and moxibustion for Parkinson's disease (PD) using complex network analysis technology, so as to provide the basis and treatment strategies for clinical acupuncture and moxibustion treatment of PD.

Methods: Relevant literature published in databases of China National Knowledge Infrastructure (CNKI), Wanfang, VIP, PubMed, and Web of Science from the inception to December of 2023 was retrieved. The literature was screened based on inclusion and exclusion criteria to establish a prescription database for acupuncture treatment of PD.

View Article and Find Full Text PDF

Introduction: Recently, "body-first" and "brain-first" subtype in Parkinson's disease (PD) was proposed based on the propagation of α-synuclein. In isolated RBD considered as a premotor stage of body-first PD, α-synuclein was supposed to originate in the enteric nervous system and spreads via autonomic nervous system. Therefore, we hypothesized that body-first PD is more likely to have a delayed gastric emptying time and reduced cardiac sympathetic denervation.

View Article and Find Full Text PDF

Therapeutic drug monitoring in Parkinson's disease.

J Neural Transm (Vienna)

October 2024

Center of Mental Health, Department of Psychiatry, Psychosomatics and Psychotherapy, University Hospital Würzburg, Margarete-Höppel Platz 1, 97080, Würzburg, Germany.

Article Synopsis
  • The therapy for Parkinson's disease (PD) is personalized to target both motor and non-motor symptoms, with adjustments needed as the disease progresses and neurodegeneration occurs.
  • Monitoring dopamine substituting drugs, particularly measuring plasma levels of levodopa, is suggested to optimize treatment efficacy and manage variability in response.
  • Limited understanding of how other medications and factors like gut motility affect levodopa levels complicates treatment; further research is needed on the interactions and impacts of multiple drugs used by PD patients.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!